niacinamide has been researched along with Psoriasis in 23 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Calcipotriene has limited efficacy in treating psoriasis." | 9.14 | Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. ( Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010) |
| "Ninety-nine patients with psoriasis were treated topically with 6-aminonicotinamide (6-AN) in four years." | 9.04 | Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. ( Zackheim, HS, 1978) |
| " The patient had a history of psoriasis vulgaris and sorafenib (SOR) was introduced (800 mg/day) because of transcatheter arterial chemoembolization (TACE) refractoriness." | 7.96 | Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma. ( Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T, 2020) |
| " The incidence of treatment-related adverse events (AEs) was also assessed." | 6.82 | The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis. ( Guo, L; Jiang, X; Wang, L; Zhang, L, 2022) |
| "Psoriasis is an immune-mediated skin disorder that affects populations worldwide." | 5.62 | Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. ( Pang, M; Tang, Y; Wang, M; Wang, W; Wang, Y; Xu, Y; Yang, X, 2021) |
| "Sorafenib treatment was initiated." | 5.42 | [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015) |
| "Clear cell renal cell carcinoma is a hypervascularized solid tumor associated with loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene and increased Raf-1 activity." | 5.36 | Sorafenib-associated remission of psoriasis in hypernephroma: case report. ( Fournier, C; Tisman, G, 2010) |
| "Calcipotriene has limited efficacy in treating psoriasis." | 5.14 | Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. ( Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010) |
| "Ninety-nine patients with psoriasis were treated topically with 6-aminonicotinamide (6-AN) in four years." | 5.04 | Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. ( Zackheim, HS, 1978) |
| " The patient had a history of psoriasis vulgaris and sorafenib (SOR) was introduced (800 mg/day) because of transcatheter arterial chemoembolization (TACE) refractoriness." | 3.96 | Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma. ( Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T, 2020) |
| " The incidence of treatment-related adverse events (AEs) was also assessed." | 2.82 | The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis. ( Guo, L; Jiang, X; Wang, L; Zhang, L, 2022) |
| " ASP015K was generally well tolerated, with no serious adverse events (AEs) reported." | 2.80 | A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. ( Akinlade, B; Ball, G; Catlin, M; Krueger, JG; Papp, K; Pariser, D; Wierz, G; Zeiher, B, 2015) |
| "Psoriasis is an inflammatory disorder characterized by a T helper type 1 cell cytokine pattern." | 2.42 | Nicotinamide: a potential addition to the anti-psoriatic weaponry. ( Namazi, MR, 2003) |
| " No other adverse effects of treatment were reported by patients during the study period." | 1.72 | Evaluation of safety and efficacy of topical 4% nicotinamide in treatment of psoriasis; among a representative sample of Egyptians (an analytical observational study). ( El-Khalawany, M; Elsheikh, M; Kadah, AS; Nouh, AH; Said, M, 2022) |
| "Psoriasis is an immune-mediated skin disorder that affects populations worldwide." | 1.62 | Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. ( Pang, M; Tang, Y; Wang, M; Wang, W; Wang, Y; Xu, Y; Yang, X, 2021) |
| "Sorafenib treatment was initiated." | 1.42 | [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015) |
| "Clear cell renal cell carcinoma is a hypervascularized solid tumor associated with loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene and increased Raf-1 activity." | 1.36 | Sorafenib-associated remission of psoriasis in hypernephroma: case report. ( Fournier, C; Tisman, G, 2010) |
| "Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors." | 1.36 | Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. ( Chon, SY; Diamantis, ML, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Guo, L | 1 |
| Wang, L | 1 |
| Jiang, X | 1 |
| El-Khalawany, M | 1 |
| Nouh, AH | 1 |
| Kadah, AS | 1 |
| Elsheikh, M | 1 |
| Said, M | 1 |
| Hsieh, CY | 1 |
| Tsai, TF | 1 |
| Plachouri, KM | 1 |
| Georgiou, S | 1 |
| Adachi, T | 1 |
| Hiraoka, A | 1 |
| Okazaki, H | 1 |
| Nagamatsu, K | 1 |
| Izumoto, H | 1 |
| Yoshino, T | 1 |
| Tsuruta, M | 1 |
| Aibiki, T | 1 |
| Okudaira, T | 1 |
| Yamago, H | 1 |
| Iwasaki, R | 1 |
| Suga, Y | 1 |
| Mori, K | 1 |
| Miyata, H | 1 |
| Tsubouchi, E | 1 |
| Ninomiya, T | 1 |
| Michitaka, K | 1 |
| Nash, P | 1 |
| Kerschbaumer, A | 1 |
| Dörner, T | 1 |
| Dougados, M | 1 |
| Fleischmann, RM | 1 |
| Geissler, K | 1 |
| McInnes, I | 1 |
| Pope, JE | 1 |
| van der Heijde, D | 1 |
| Stoffer-Marx, M | 1 |
| Takeuchi, T | 1 |
| Trauner, M | 1 |
| Winthrop, KL | 1 |
| de Wit, M | 1 |
| Aletaha, D | 1 |
| Baraliakos, X | 1 |
| Boehncke, WH | 1 |
| Emery, P | 1 |
| Isaacs, JD | 1 |
| Kremer, J | 1 |
| Lee, EB | 1 |
| Maksymowych, WP | 1 |
| Voshaar, M | 1 |
| Tam, LS | 1 |
| Tanaka, Y | 1 |
| van den Bosch, F | 1 |
| Westhovens, R | 1 |
| Xavier, R | 1 |
| Smolen, JS | 1 |
| Yang, X | 1 |
| Tang, Y | 1 |
| Wang, M | 1 |
| Wang, Y | 1 |
| Wang, W | 1 |
| Pang, M | 1 |
| Xu, Y | 1 |
| Cline, A | 1 |
| Cardwell, LA | 1 |
| Feldman, SR | 1 |
| Papp, K | 1 |
| Pariser, D | 1 |
| Catlin, M | 1 |
| Wierz, G | 1 |
| Ball, G | 1 |
| Akinlade, B | 1 |
| Zeiher, B | 1 |
| Krueger, JG | 1 |
| Nakagawa, T | 1 |
| Chubachi, S | 1 |
| Yiu, ZZ | 2 |
| Ali, FR | 1 |
| Griffiths, CE | 1 |
| Warren, RB | 1 |
| Fournier, C | 1 |
| Tisman, G | 1 |
| Diamantis, ML | 1 |
| Chon, SY | 1 |
| Levine, D | 1 |
| Even-Chen, Z | 1 |
| Lipets, I | 1 |
| Pritulo, OA | 1 |
| Svyatenko, TV | 1 |
| Andrashko, Y | 1 |
| Lebwohl, M | 1 |
| Gottlieb, A | 1 |
| Laquer, V | 1 |
| Saedi, N | 1 |
| Dann, F | 1 |
| Kelly, K | 1 |
| Kanda, N | 1 |
| Hau, CS | 1 |
| Tada, Y | 1 |
| Tatsuta, A | 1 |
| Sato, S | 1 |
| Watanabe, S | 1 |
| Hung, CT | 1 |
| Chiang, CP | 1 |
| Wu, BY | 1 |
| Maki, N | 1 |
| Komine, M | 1 |
| Takatsuka, Y | 1 |
| Maekawa, T | 1 |
| Murata, S | 1 |
| Ohtsuki, M | 1 |
| Namazi, MR | 1 |
| SERRA, O | 1 |
| PRADO, H | 1 |
| Zackheim, HS | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis[NCT01096862] | Phase 2 | 124 participants (Actual) | Interventional | 2010-03-23 | Completed | ||
| Evaluation of Topical Nicotinamide in Combination With Calcipotriol Compared With Calcipotriol Alone for the Treatment of Mild to Moderate Psoriasis.[NCT01763424] | Phase 2/Phase 3 | 66 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for niacinamide and Psoriasis
| Article | Year |
|---|---|
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Topics: Adamantane; Azetidines; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Janus Kinase Inhib | 2022 |
Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.
Topics: Acitretin; Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Biological Factors; Biologi | 2022 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piper | 2020 |
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; | 2021 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 | 2017 |
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compo | 2016 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic | 2016 |
Nicotinamide: a potential addition to the anti-psoriatic weaponry.
Topics: Animals; Anti-Inflammatory Agents; Mice; Niacinamide; Psoriasis | 2003 |
4 trials available for niacinamide and Psoriasis
| Article | Year |
|---|---|
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
Topics: Adamantane; Biopsy; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2015 |
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.
Topics: Adult; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Synergism; Drug Therapy, Combinati | 2010 |
Treatment of psoriasis with 6-aminonicotinamide.
Topics: Acid-Base Equilibrium; Administration, Oral; Administration, Topical; Adult; Aged; Amines; Biopsy; C | 1975 |
Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis.
Topics: 6-Aminonicotinamide; Administration, Topical; Aged; Animals; Anti-Inflammatory Agents; Clinical Tria | 1978 |
11 other studies available for niacinamide and Psoriasis
| Article | Year |
|---|---|
Evaluation of safety and efficacy of topical 4% nicotinamide in treatment of psoriasis; among a representative sample of Egyptians (an analytical observational study).
Topics: Administration, Topical; Dermatologic Agents; Egypt; Emollients; Female; Humans; Male; Niacinamide; | 2022 |
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Live | 2020 |
Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy.
Topics: Administration, Topical; Animals; Imiquimod; Methotrexate; Mice; Mice, Inbred BALB C; Niacinamide; P | 2021 |
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans | 2015 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neopl | 2010 |
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metast | 2010 |
Sorafenib-associated psoriasiform skin changes.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hand; Humans; Male; Middle Aged; Niacinami | 2010 |
Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes.
Topics: Animals; Cells, Cultured; Chemokine CCL20; Chemokine CXCL10; Female; Humans; I-kappa B Kinase; Inter | 2011 |
Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
Topics: Antineoplastic Agents; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compou | 2012 |
Pustular eruption induced by sorafenib in a case of psoriasis vulgaris.
Topics: Aged; Asian People; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psor | 2013 |
[New treatment for psoriasis].
Topics: Ascorbic Acid; Corrinoids; Folic Acid; Hematinics; Humans; Methyltestosterone; Niacin; Niacinamide; | 1962 |